Skip navigation

Currently Being Moderated

Merck Quits Testing New HIV Treatment

Posted by linyuer on Dec 1, 2010 6:57:05 PM

beats by dre Merck & Co reportedly decided on Monday to stop testing its HIV drug  Isentress after preliminary trial results showed the treatment was not  as effective as the standard treatment or control treatment.Isentress  brought the company an annual sales of $777 million for the first nine  months in 2009, according to Reuters.The difference was found dr dre beats mostly among those with a high viral load, meaning that the once-daily  dose may not be enough to suppress the viral growth.      The study showed after a 48-week treatment, 83.2 percent of those  treated with the once-daily dose lowered their HIV loads to an  undetectable viral level, compared to 88.9 percent of those treated with  a twice-daily dose of Isentress.  The monster beats difference is statistically significant.    According to the Centers for Disease Control and  Prevention, more than one monster headphones million Americans live with HIV and 21 percent percent are unaware   that they are HIV carriers.An estimated 18,000 people die from AIDS each  year in the United States.There are about 48 drugs the FDA approved to  treat AIDS/HIV including AccessPak for HIV PEP Basic, Agenerase,  Aptivus, Combivir, Crixivan, Epivir, Epzicom, Gammagard, intelence,  Isentress, Kaletra, Norvir, Prezista, Privigen, Retrovir, Reyataz,  Sustiva, Truvada, Viramune, Viread, and Ziagen hip hop beats.

Comments (0)